SYNDEXA Trademark

Trademark Overview

On Tuesday, November 7, 2006, a trademark application was filed for SYNDEXA with the United States Patent and Trademark Office. The USPTO has given the SYNDEXA trademark a serial number of 77038687. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 21, 2013. This trademark is owned by Syndexa Pharmaceuticals Corporation. The SYNDEXA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

pharmaceutical and biopharmaceutical preparations for treating inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases

pharmaceutical research and development services relating to the treatment of inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases; consulting services in the fields of pharmaceutical research and development relating to pharmaceutical and biopharmaceutical preparations for treating inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases
syndexa

General Information

Serial Number77038687
Word MarkSYNDEXA
Filing DateTuesday, November 7, 2006
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 21, 2013
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 14, 2010

Trademark Statements

Goods and Servicespharmaceutical and biopharmaceutical preparations for treating inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases
Goods and Servicespharmaceutical research and development services relating to the treatment of inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases; consulting services in the fields of pharmaceutical research and development relating to pharmaceutical and biopharmaceutical preparations for treating inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 13, 2006
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, November 5, 2010
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSyndexa Pharmaceuticals Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWellesley, MA 02482
Party NameSyndexa Pharmaceuticals Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWellesley, MA 02482

Trademark Events

Event DateEvent Description
Monday, October 21, 2013ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 21, 2013ABANDONMENT - NO USE STATEMENT FILED
Wednesday, March 20, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 18, 2013EXTENSION 1 GRANTED
Monday, March 18, 2013EXTENSION 1 FILED
Monday, March 18, 2013TEAS EXTENSION RECEIVED
Monday, March 18, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 18, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, June 1, 2012PAPER RECEIVED
Tuesday, August 7, 2012TTAB RELEASE CASE TO TRADEMARKS
Tuesday, August 7, 2012OPPOSITION TERMINATED NO. 999999
Tuesday, August 7, 2012OPPOSITION DISMISSED NO. 999999
Monday, June 13, 2011OPPOSITION INSTITUTED NO. 999999
Thursday, January 13, 2011EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, December 14, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 14, 2010PUBLISHED FOR OPPOSITION
Monday, November 8, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, November 5, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 5, 2010EXAMINER'S AMENDMENT ENTERED
Friday, November 5, 2010NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, November 5, 2010EXAMINERS AMENDMENT E-MAILED
Friday, November 5, 2010EXAMINERS AMENDMENT -WRITTEN
Friday, November 5, 2010LIE CHECKED SUSP - TO ATTY FOR ACTION
Friday, November 5, 2010ASSIGNED TO LIE
Tuesday, May 4, 2010REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, November 4, 2009REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, November 4, 2009ASSIGNED TO LIE
Monday, May 4, 2009REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, May 4, 2009ASSIGNED TO LIE
Tuesday, November 4, 2008REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, May 2, 2008REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, May 2, 2008ASSIGNED TO LIE
Friday, November 2, 2007NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, November 2, 2007LETTER OF SUSPENSION E-MAILED
Friday, November 2, 2007SUSPENSION LETTER WRITTEN
Monday, September 17, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, September 17, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 17, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 17, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 15, 2007NON-FINAL ACTION E-MAILED
Thursday, March 15, 2007NON-FINAL ACTION WRITTEN
Thursday, March 15, 2007ASSIGNED TO EXAMINER
Monday, November 13, 2006NEW APPLICATION ENTERED IN TRAM

Related Keywords

syndexa diseases pharmaceutical neurodegenerative disorders metabolic cardiovascular inflammatory services relating research